Human Cell — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Founded in 2015, Human Cell Corporation operates at the intersection of cell therapy and regenerative medicine, providing critical enabling tools for the broader industry. Its core offering is a suite of engineered cytokines that are long-acting and free of animal-derived components, which are essential for the expansion and differentiation of therapeutic cells like stem cells and immune cells. By also providing high-purity protein manufacturing services, the company supports both the research and development phases of biotech and pharma partners. Human Cell appears to be a private, platform-and-services company catering to the growing cell therapy manufacturing sector.

Cell TherapyRegenerative Medicine

Technology Platform

Proprietary HEK293 cell-based platform for producing long-acting and xeno-free recombinant cytokines and growth factors.

Opportunities

The rapid expansion of the cell therapy market creates a growing, addressable demand for high-quality, specialized manufacturing components.

The company's focus on xeno-free and long-acting cytokines directly addresses key industry pain points around cost, scalability, and regulatory compliance.

There is further opportunity to expand into GMP manufacturing services and form strategic partnerships with larger CDMOs or therapeutic developers.

Risk Factors

Intense competition from large, established life science reagent companies and CDMOs with greater resources and market reach.

Dependency on the success and funding cycles of the broader cell therapy industry, which is still maturing.

Execution risks related to scaling production, maintaining product quality, and protecting intellectual property as a small, private entity.

Competitive Landscape

Human Cell competes in the life science tools and services space, specifically against large reagent suppliers (e.g., Thermo Fisher Scientific, Sartorius, Miltenyi Biotec) that offer broad portfolios of cytokines and cell culture media. It also faces competition from specialized CDMOs and smaller biotech firms that develop engineered growth factors. Differentiation hinges on the demonstrated performance benefits of its long-acting, HEK293-derived, xeno-free cytokine platform.

More companies in Cell & Gene Therapy →More companies in United States →